Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
3M's biggest opportunity lies in scaling its proprietary Expanded Beam Optics (EBO) architecture across 44 hyperscaler and semiconductor ecosystem partners.
Operational turnaround margin expansion stalls as consolidated operating margin falls below 18.5% over the next 18 months, 3 percentage points below intermediate turnaround targets.
While operational execution under new leadership is progressing, current market pricing embeds unrealistic long-term earnings growth expectations and leaves investors highly vulnerable to post-2027 buyback deceleration and persistent litigation cash drains.2
Valuation Disconnect and Implied Expectations: 3M Company trades at $169.55, representing an NTM forward P/E multiple of 17.83x and a market capitalization of $87.44B. Diagnostic reverse DCF analysis confirms that the prevailing stock price implies 10.83% annual growth over ten years, well above analyst consensus of 8.04%.12
Operational Restructuring Progress Versus Macro Friction: In FY2025, 3M generated $24,948M in revenue and $4,629M in operating income, establishing an 18.55% operating margin. Operational restructuring is led by the core Safety & Industrial segment, which delivered $2,836M in operating profit on $11,384M in revenue (24.91% margin). Management guided toward ~25% operating margins by 2027 with ~100 bps expansion in the second half of 2026. However, margin gains face persistent friction from $150M–$175M in oil-based feedstock inflation and $110M in tariff and Strata cost headwinds, alongside industrial volume sluggishness in EMEA ($4,274M revenue, 17.1% of FY2025 total) and China/Hong Kong ($2,951M revenue, 11.8% of FY2025 total).356
Cash Flow Impairment from Litigation Liabilities: Operating cash flow conversion remains materially constrained by multi-year cash settlements for public water PFAS systems and Combat Arms earplug litigation. For FY2025, operating cash flow stood at $2,306M against GAAP net income of $3,250M, resulting in an operating cash flow to net income ratio of 0.7095, well below the healthy 0.80x benchmark. Free cash flow of $1,396M after $910M in capital expenditures reflects ongoing cash absorption from settlement disbursements that will limit balance-sheet flexibility.45
Impending Buyback Deceleration and Multiple De-Rating Risk: EPS growth has been heavily subsidized by the $10B+ capital return program through 2027, under which $8.6B has already been deployed through Q2 2026, including $3B in H1 2026 at an average price of ~$153. This drove diluted share count down from 553.9M in FY2023 to 541.3M in FY2025, with 515.72M shares outstanding as of September 2026. With only ~$1.4B in remaining authorization, share repurchase accretion will drop sharply. As buyback tailwinds dissipate and the approved house forecast projects EPS contraction post-FY2027 (-2.28% in FY2028, -3.38% in FY2029, -4.35% in FY2030), the current 17.83x multiple faces severe de-rating pressure toward 14.5x, confirming our Sell recommendation.235
3M is doubling manufacturing capacity twice over 12 to 18 months for its patented Expanded Beam Optics interconnect platform across 44 hyperscaler and component partners, positioning the company to capture high-margin revenue as the addressable market grows from $1B in 2026 to $2B by 2028.3
The core Safety & Industrial business represents a resilient foundation, delivering $2,836M in operating profit on $11,384M in revenue in FY2025 (24.91% segment margin), anchoring management's pathway toward ~25% consolidated operating margins by 2027.36
Management has demonstrated commitment to shareholder returns, deploying $8.6B of its $10B+ capital return authorization since 2025 ($3B repurchased in H1 2026 at ~$153 per share), successfully reducing diluted share count from 553.9M in FY2023 to 541.3M in FY2025 and 515.72M in September 2026.
Sell. 3M Company is executing credibly on operational restructuring following the Solventum spin-off, but the market price of $169.55 has significantly outrun economic reality, trading at an unjustified 58.3% premium to fair value of $107.08. With $8.6B of the $10B+ share repurchase program already completed, ongoing multi-year litigation settlement cash outflows (FY2025 OCF of $2,306M vs net income of $3,250M), and negative EPS growth modeled post-FY2027, the risk-reward profile is decisively negative.235
Developing employees contributes to growing 3M’s business. 3M maintains talent and succession planning processes, including regular reviews by the Company’s chief executive officer (CEO) and reporting up through the Board of Directors. The Company provides leadership development experiences through enterprise leadership development programs, job-based or project-based assignments, assessment and coaching, and targeted skill-development where leaders are given the opportunity to learn, apply, and share their skills. 3M also provides opportunities for all employees to learn, in addition to regular coaching and support from their supervisor.
With the Company’s global online employee learning platform, employees are able to access unique, just-in-time development resources in over 15 languages to support their career aspirations and advance their skills.
In a severe operating stress test, 3M faces compounding margin pressure and cash absorption that derail turnaround progress. Consolidated operating margins compress toward 18.5%, driven by $150M-$175M in unhedged raw material cost inflation and $110M in persistent tariff and Strata system separation costs that outpace pricing actions. Concurrently, broader industrial recession across EMEA ($4,274M FY2025 revenue) and China ($2,951M FY2025 revenue), combined with ongoing channel destocking and double-digit declines in consumer electronic devices, depresses top-line organic growth to near-flat levels. Meanwhile, non-operating litigation payouts for municipal water PFAS filtration and Combat Arms earplugs persist at high run rates, trapping operating cash flow and keeping cash conversion depressed at 0.7095. With $8.6B of the $10B+ capital return program exhausted, share count reduction ceases to buffer per-share results, causing EPS compounding to fall toward 3.5% and forcing valuation multiple contraction to 14.5x.
3M Company's competitive moat is evaluated as Narrow, anchored by proprietary materials science intellectual property, established brand trust in regulated safety equipment, and customer switching costs embedded across industrial and transportation assembly processes. In core Safety & Industrial, which contributed $11,384M in revenue and $2,836M in operating income in FY2025 (24.91% segment operating margin), 3M manufactures specialized adhesives, abrasives, and personal protection solutions that require rigorous specification testing and regulatory approvals, dissuading customer substitution.
In high-speed data communications, 3M has developed a technological moat through its Expanded Beam Optics (EBO) architecture. Backed by significant patent protection, EBO provides mechanical durability and reduced contamination sensitivity relative to traditional physical-contact optical transceivers. Recognizing that hyperscale data center operators avoid single-source dependence, 3M established a multi-supplier agreement licensing the technology across 44 ecosystem participants, including major hyperscalers, chipmakers, and connector manufacturers. While currently generating $40M to $50M in annual , the addressable market is targeted to expand to $2B by 2028, providing differentiated optionality within Transportation & Electronics ($8,272M FY2025 revenue).
None of the valuation methods used to calculate Fair value relies on a separate assumption about how long the competitive advantage lasts.
The highlighted cell is Fair value when every assumption sits at its base level ($107.08). Each row and column shows what Fair value becomes when one assumption moves.
Free cash flow to the firm stays positive in the first projected year at $3.1B after modeled reinvestment of $866.5M, with terminal value at 76.0% of enterprise value. A sudden drop in free cash flow is not projected unless capital spending relative to , reinvestment, or resets materially.
Even in an operational beat scenario, valuation at $169.55 remains at an extreme premium to fair value ($107.08), while buyback authorization exhaustion and multi-year litigation settlement cash drains prevent a rating upgrade, maintaining the Sell rating.
Industrial benchmark data shows capex-to-revenue of 2.3% and capex-to-depreciation of 1.35x. 3M maintains disciplined reinvestment with FY2025 capex of $910M against $1,308M in depreciation, even as it doubles manufacturing capacity in Expanded Beam Optics.35
In a broader industrial expansion, accelerated factory automation, infrastructure renewal, and hyperscaler AI infrastructure investments boost volumes across Safety & Industrial ($11,384M FY2025 revenue) and Transportation & Electronics ($8,272M FY2025 revenue), enabling operating margins to exceed 25% by 2027.
In an industrial downturn, contraction in European manufacturing ($4,274M EMEA revenue) and China ($2,951M revenue), paired with high-teens declines in consumer electronic devices and retail destocking, compresses plant absorption and stalls margin progression.
Given our active Sell recommendation and the substantial 58.3% premium of current market prices ($169.55) over house Fair value ($107.08), no portfolio exposure is warranted. Investors face asymmetric downside risk as share repurchases wind down ($8.6B executed of $10B+ authorization) and ongoing litigation settlement payouts drain cash flow.23
Risk management strictly mandates full divestment given 3M's Sell rating and 58.3% valuation premium over fair value ($107.08 vs $169.55). Institutional holders should avoid averaging down and manage exit liquidity across active trading windows. The primary upside risk to a short or underweight stance stems from faster-than-expected commercial monetization of Expanded Beam Optics in AI data centers ($2B TAM by 2028); however, this is mitigated by 3M's small current revenue base ($40M-$50M in FY2026) and the requirement to share economics across 44 ecosystem partners. Downside protection should be prioritized by executing exits before post-2027 share repurchase depletion becomes consensus knowledge.
Value investors should avoid MMM at $169.55, as the stock offers negative margin of safety (-36.84% to fair value midpoint of $107.08). Forward earnings multiple of 17.83x fails to reflect the drag of $13,160M in total debt and recurring multi-year litigation settlement cash outflows.2
Growth investors should avoid MMM because organic top-line volume growth remains modest across mature multi-industrial segments. FY2025 revenue grew to $24,948M, and while Expanded Beam Optics represents an exciting high-growth opportunity in AI data centers ($1B TAM in 2026 reaching $2B by 2028), it remains a nascent business in the $40M to $50M range today, insufficient to overcome broader industrial deceleration in Europe and Asia-Pacific.3
While operational restructuring following the Solventum separation is advancing, market expectations have far outpaced economic reality, pricing in an aggressive 17.83x forward P/E multiple and requiring 10.83% long-term earnings compounding against consensus expectations of 8.04%.2
The risk-reward balance is decisively unfavorable. Share repurchase accretion is set to taper dramatically as $8.6B of the $10B+ capital return program through 2027 has already been completed through Q2 2026 ($3B executed in H1 2026 at ~$153 per share). Concurrently, multi-year cash disbursements for legacy PFAS drinking water and Combat Arms earplug settlements continue to impair cash flow conversion, keeping FY2025 operating cash flow at $2,306M against net income of $3,250M. With the house forecast projecting negative EPS growth post-FY2027 (-2.28% in FY2028, -3.38% in FY2029, and -4.35% in FY2030), investors face substantial valuation de-rating toward 14.5x.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
The records this analysis drew on, as they stood when it was run.
In the bear case, European and Chinese industrial demand contracts, while retail channel destocking lingers in Consumer. Cash settlement requirements for PFAS drinking water remediation increase, keeping operational cash conversion depressed. Operating margins stall, per-share earnings growth slows materially, and the valuation multiple compresses toward discounted peer levels.
FY2025 operating income of $4,629M on $24,948M revenue established an 18.55% margin. Management guided H2 margin expansion of ~100 bps, but faced $110M tariff/Strata cost headwinds and $150-$175M oil-based input inflation. If consolidated margin falls 3 percentage points below the 21.5% target to 18.5%, operating income and free cash flow targets are severely missed.35
Terminal multiple policy currently assumes 17.5x. With $8.6B of the $10B+ capital return authorization already executed, share repurchase support declines sharply, while the house forecast schedule projects EPS contraction post-FY2027 (-2.28% in FY2028, -3.38% in FY2029, -4.35% in FY2030), triggering a 20% valuation de-rating to 14.0x.23
The five developments that would weaken our investment case.
Consolidated operating margin failing to advance past the 18.55% FY2025 baseline indicates that $150M-$175M in raw chemical input inflation and $110M in tariff and Strata headwinds are neutralizing manufacturing productivity gains.
Current:18.55% in FY2025
Alert if<18.50%
Operating cash flow to net income remaining below 0.70x (FY2025 OCF of $2,306M vs net income of $3,250M) demonstrates that ongoing PFAS and Combat Arms settlement disbursements are consuming operational liquidity.
Current:0.7095 in FY2025
Alert if<0.7000
De-rating of the forward valuation multiple below 15.0x from current 17.83x confirms market re-pricing of post-FY2027 EPS contraction and dwindling buyback support.
Current:17.83x as of 2026-09-27
Alert if<15.00x
Optical interconnect revenue failing to scale beyond $100M by FY2027 indicates that ecosystem adoption across 44 partners is faltering against rival connectivity standards.
Current:$40M - $50M in FY2026
Alert if<$100M by FY2027
Quarterly share repurchases dropping below $300M signals the final depletion of the $10B+ capital return authorization ($8.6B executed through Q2 2026), removing the buyback bid that has supported share prices and exposing post-FY2027 negative EPS growth.
Current:$1.0B in Q2 2026
Alert if<$300M per quarter
Despite these advantages, structural liabilities prevent 3M from achieving a Wide moat rating. The Consumer segment ($4,920M revenue, $996M operating income in FY2025) exhibits vulnerability to retail inventory destocking and private-label competition. More critically, multi-year cash disbursements associated with PFAS drinking water settlements and Combat Arms earplug litigation continue to burden free cash flow conversion, with FY2025 operating cash flow of $2,306M trailing net income of $3,250M. These ongoing legal cash requirements dilute returns on capital and constrain corporate reinvestment relative to pure-play industrial peers.
3M generates positive economic profit with an ROIC of 21.35% exceeding its moderate cost of capital (WACC of 8.7047% and cost of equity of 9.2707%). The core Safety & Industrial business underpins this economic profit, generating $2,836M of operating profit on $11,384M of revenue (24.91% segment margin) in FY2025. However, reported net income of $3,250M translated into only $2,306M of operating cash flow (0.7095 conversion ratio), showing that multi-year litigation settlement disbursements dilute realized cash returns.156
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
Apply a terminal P/E to the dated forward EPS path, then discount that future share value back to the analysis date.
Convert the revenue and margin path into after-tax free cash flow, discount the annual per-share amounts and at , then adjust for signed per current share.
Add depreciation to net income, subtract maintenance capex, divide by diluted shares, and apply a normalized valuation multiple.
Value each distinct segment, subtract corporate overhead and net debt, add probability-weighted optionality, and divide by diluted shares.
Solve for the growth rate that makes the model value equal the report-date share price.
In the base case, 3M executes its turnaround plan following the Solventum healthcare spin-off. Operating margins expand from 18.55% in FY2025 to 19.37% in FY2026 and 20.38% in FY2027, reaching 21.42% by FY2030. The core Safety & Industrial business provides steady profitability ($2,836M EBIT in FY2025), while Transportation & Electronics benefits from gradual optical growth. However, because $8.6B of the $10B+ capital return authorization has already been executed, buyback support tapers sharply, resulting in post-FY2027 EPS growth slowing to -2.28% in FY2028 and -3.38% in FY2029.356
In the upside scenario, operational restructuring accelerates operating margins beyond 25% by 2027 ahead of guidance. 3M's Expanded Beam Optics platform establishes standard interconnect architecture across 44 hyperscaler and semiconductor ecosystem partners, scaling toward a $2B addressable market by 2028. Robust free cash generation supports over $10B in capital returns, driving 11.5% EPS CAGR and multiple expansion toward peer median of 19.5x.3
Inline performance confirms the house forecast schedule ($8.94 EPS in FY2026), confirming that current valuation multiple of 17.83x forward P/E is excessive relative to post-2027 decelerating fundamentals, maintaining the Sell rating.
An operational miss exposes the fragility of turnaround margin expansion against $150M-$175M of raw material inflation and $110M tariff/Strata headwinds, catalyzing an aggressive valuation multiple contraction toward discounted peer multiples and requiring an immediate exit at the Sell rating.
3M's earnings quality displays divergence between reported GAAP accruals and realized cash conversion. While FY2025 operating income of $4,629M and net income of $3,250M demonstrate operational stabilization post-Solventum, operating cash flow of $2,306M reflects cash conversion depressed by non-operational outlays. This drag is driven by substantial non-operational cash disbursements under the multi-year public water PFAS and Combat Arms settlement agreements, which will continue to siphon operating cash flow away from equity holders despite positive GAAP net income.5
Management committed to doubling manufacturing capacity twice over 12-18 months to tap a $2B TAM by 2028; adoption across the 44-partner ecosystem is vital for growth optionality.3
Oil-based chemical inflation is estimated at $150M-$175M for FY2026, requiring ~2% back-half pricing realization to maintain neutral spread.3
With $8.6B executed out of the $10B+ program through Q2 2026, capital return support will taper sharply after FY2026.3
Operating cash flow conversion in FY2025 was constrained by litigation disbursements; cash flow normalization requires operational cash generation to rebound toward historical earnings levels.5
| $35.36B |
| $26.16B |
| $24.61B |
| $24.58B |
| $24.95B |
| -8.3% |
| Gross profit | $16.61B | $14.97B | $14.20B | $10.08B | $9.87B | -12.2% |
| Operating income | $7.37B | $4.37B | $-10.69B | $4.82B | $4.63B | -11.0% |
| Net income | $5.92B | $5.78B | $-7.00B | $4.17B | $3.25B | -13.9% |
| EPS (diluted) | $10.12 | $10.18 | $-12.63 | $7.55 | $6.00 | -12.3% |
| EBITDA | $9.58B | $8.72B | $-9.13B | $7.23B | $5.85B | -11.6% |
| R&D | $1.20B | $800.0M | $700.0M | $700.0M | $1.17B | -0.7% |
| SG&A | $7.20B | $7.23B | $19.20B | $4.22B | $4.00B | -13.7% |
In FY2025, 3M generated $2,306M in operating cash flow and invested $910M in capital expenditures, yielding free cash flow of $1,396M. The operating cash flow to net income ratio of 0.7095 (OCF of $2,306M on net income of $3,250M) demonstrates substantial cash absorption from legacy litigation settlements and working capital friction. While management raised full-year free cash flow expectations during the Q2 call, sustained free cash flow expansion requires overcoming $150M-$175M in raw material inflation headwinds and ongoing PFAS municipal settlement payouts.345
3M's capital allocation has prioritized aggressive equity shrinkage and dividend rebasing following the Solventum healthcare separation. Under its $10B+ shareholder return authorization through 2027, the company has already returned $8.6B through Q2 2026, including $1B repurchased in Q2 and ~$3B in H1 2026 at an average price of ~$153. This program reduced diluted shares from 553.9M in FY2023 to 541.3M in FY2025, with current shares outstanding at 515.72M. However, with only ~$1.4B in remaining authorization, share buyback accretion will sharply decelerate after 2026. Total debt stands at $13,160M, representing a 13.08% debt weighting in total capital, requiring balanced capital preservation against multi-year legal settlement liabilities.
3M's return on invested capital is recovering following the spin-off of Solventum and the settlement of legacy PFAS drinking water and Combat Arms litigation, with FY2025 operating income reaching $4,629M and net income rebounding to $3,250M. While ROIC currently measures 21.35%, maintaining this level requires driving operating margins from 18.55% in FY2025 toward 21.42% in FY2030.
ROIC of 21.35% comfortably exceeds the moderate WACC of 8.7047% and cost of equity of 9.2707%, generating a healthy positive economic spread.
Safety & Industrial delivered $2,836M in operating income on $11,384M in revenue in FY2025 (24.91% margin), outperforming Transportation & Electronics (17.36% margin on $8,272M revenue) and Consumer (20.24% margin on $4,920M revenue).
Consolidated turnaround performance is overwhelmingly dependent on preserving operating margins and distribution access in Safety & Industrial.
Operating cash flow was $2,306M in FY2025 against net income of $3,250M, establishing an OCF-to-net income conversion ratio of only 0.7095, leaving free cash flow at $1,396M after $910M in capex.
Multi-year legal settlement disbursements create a structural cash drain that depresses equity free cash flow conversion relative to reported accounting net income.
3M has already executed $8.6B of its $10B+ capital return commitment through Q2 2026, including $1B repurchased in Q2 and ~$3B in H1 2026 at an average price of ~$153.
With only ~$1.4B in repurchases remaining through 2027, share count reduction will slow dramatically from the pace that reduced shares from 553.9M in FY2023 to 541.3M in FY2025, uncovering underlying EPS contraction in FY2028-FY2030.
| Revenue | $6,500,000,000 |
|---|---|
| Cost of revenue | $3,817,000,000 |
| Gross profit | $2,683,000,000 |
| Operating expenses | $1,699,000,000 |
| Operating income | $984,000,000 |
| Non-operating items and tax | -$51,000,000 |
| Net income | $933,000,000 |
| Total assets | $37,733,000,000 |
|---|---|
| Cash | $5,235,000,000 |
| Current assets | $16,387,000,000 |
| Total liabilities | $32,986,000,000 |
| Current liabilities | $9,595,000,000 |
| Shareholders’ equity | $4,747,000,000 |
| Net income | $3,250,000,000 |
|---|---|
| Operating inflow | $4,783,000,000 |
| Depreciation and amortization | $1,308,000,000 |
| Stock-based compensation | $225,000,000 |
| Operating cash flow | $2,306,000,000 |
| Operating outflow | $2,477,000,000 |
| Cash available | $9,297,000,000 |
| Beginning cash | $5,600,000,000 |
| Investing inflow | $1,350,000,000 |
| Exchange-rate effect | $41,000,000 |
| Financing outflow | $4,016,000,000 |
| Ending cash | $5,235,000,000 |
| Investing cash flow | $1,350,000,000 |
| Financing cash flow | -$4,016,000,000 |
Point-in-time financial data used in the 2026-09-27 analysis.
| Period | Revenue | EBITDA | Net income | Operating cash flow | Free cash flow | Capex | Depreciation and amortization | Stock-based compensation | Share repurchases | Dividends paid | Net debt issuance | Investing cash flow | Financing cash flow | Beginning cash | Ending cash | Cash and investments | Total debt | Operating margin | ROIC | WACC | ROIC − WACC spread |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2016-12-31 | $30.1B | $8.7B | $5.1B | $6.7B | $5.2B | $1.4B | $1.5B | $298M | $3.8B | $2.7B | — | -$1.4B | -$4.6B | — | $2.4B | $2.7B | $11.5B | 23.3% | — | 5.9% | — |
| 2017-12-31 | — | $9.2B | $4.9B | $6.2B | $4.9B | $1.4B | $1.5B | $324M | $2.1B | $2.8B | — | -$3.1B | -$2.7B | $2.4B | $3.1B | $4.1B | $13.2B | — | — | 6.0% | — |
| 2018-12-31 | $32.8B | $8.7B | $5.3B | $6.4B | $4.9B | $1.6B | $1.5B | $302M | $4.9B | $3.2B | — | $222M | -$6.7B | $3.1B | $2.9B | $3.2B | $14.2B | 22.0% | — | 6.3% | — |
| 2019-12-31 | $32.1B | $7.7B | $4.5B | $7.1B | $5.4B | $1.7B | $1.6B | $278M | $1.4B | $3.3B | — | -$6.4B | -$1.1B | $2.9B | $2.4B | $2.5B | $19.4B | 19.2% | — | 5.3% | — |
| 2020-12-31 | $32.2B | $9.3B | $5.4B | $8.1B | $6.6B | $1.5B | $1.9B | $262M | $368M | $3.4B | — | -$580M | -$5.3B | $2.4B | $4.6B | $5B | $18.8B | 22.3% | — | 3.8% | — |
| 2021-12-31 | $35.4B | $9.6B | $5.9B | $7.5B | $5.9B | $1.6B | $1.9B | $274M | $2.2B | $3.4B | — | -$1.3B | -$6.1B | $4.6B | $4.6B | $4.8B | $17.3B | 20.8% | — | 4.5% | — |
| 2022-12-31 | $26.2B | $8.7B | $5.8B | $5.6B | $3.8B | $1.7B | $1.8B | $263M | $1.5B | $3.4B | -$838M | -$1B | -$5.4B | $4.6B | $3.7B | $3.9B | $15.9B | 16.7% | — | 6.9% | — |
| 2023-12-31 | $24.6B | -$9.1B | -$7B | $6.7B | $5.1B | $1.6B | $2B | $274M | $33M | $3.3B | -$46M | -$1.2B | -$3.1B | $3.7B | $5.9B | $6B | $14.2B | -43.4% | — | — | — |
| 2024-12-31 | $24.6B | $7.2B | $4.2B | $1.8B | $638M | $1.2B | $1.4B | $289M | $1.8B | $2B | $5.5B | -$3.2B | $1.1B | $5.9B | $5.6B | $7.7B | $13B | 19.6% | — | 7.5% | — |
| 2025-12-31 | $24.9B | $5.9B | $3.3B | $2.3B | $1.4B | $910M | $1.3B | $225M | $3.3B | $1.6B | -$716M | $1.4B | -$4B | $5.6B | $5.2B | $5.9B | $12.6B | 18.6% | — | 7.4% | — |
3M Company (MMM) trades at 17.8x forward earnings against a peer median of 21.6x. Its EV/EBITDA of 14.7x compares with a peer median of 15.3x. The comparison uses 4 peers: Honeywell International Inc., The Boeing Company, CSX Corporation and Emerson Electric Co., as of 2026-09-27.
3M occupies a diversified position across multi-industrial end markets ($24,948M consolidated revenue), but lags premier peers in margin stability and valuation multiple. While peer Honeywell demonstrates operating margins of 20.25% and trades at a forward P/E of 21.39x, 3M delivered an 18.55% operating margin in FY2025 and trades at 17.83x forward P/E. The company's geographic exposure is balanced across the Americas ($13,579M), Asia Pacific ($7,095M), and EMEA ($4,274M), but ongoing litigation cash settlements and consumer channel volatility constrain its ability to re-rate to peer median multiples (peer median forward P/E 21.61x).256
| Level | Action | Why |
|---|---|---|
| >$168.00 | Full Liquidation / Exit Position | At prices above $168.00 (September 25, 2026 share price of $169.55), the stock trades above the upper boundary of our fair value range ($126.36), offering an exceptional exit valuation. |
| $160.00 - $168.00 | Secondary Liquidation Tranche | Any technical retracements or liquidity events should be used to liquidate all remaining residual shares before fundamental multiple de-rating toward fair value ($107.08). |
Income-oriented investors should avoid allocating new capital to MMM. While the rebased dividend of $3.12 per share provides a yield baseline following the Solventum spin-off, capital return has been overwhelmingly concentrated in share repurchases ($8.6B executed out of $10B+ through Q2 2026). As buybacks wind down post-2027 and PFAS cash settlement disbursements persist (FY2025 OCF of $2,306M vs net income of $3,250M), dividend growth will be constrained.35
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
| The Boeing Company |
| $156.4B |
| 48.4x |
| 1.7x |
| 173.5% |
| 0.0% |
| CSX | CSX Corporation | $86.7B | 20.6x | 6.0x | 15.3x | 24.4% | 38.4% |
| EMR | Emerson Electric Co. | $88.6B | 21.8x | 4.8x | 16.5x | 12.8% | 26.9% |
